EGFR and melanoma: We conclude that dual inhibition of EGFR and MET provides greater response in cancer cells, which is construed as decrease of invasive abilities by reduction of protrusive activity, in comparison to monotherapy that may contribute to development of more efficient anti-melanoma therapy for patients exhibiting overexpression of these growth factor receptors.